HIRSH
et al., AHA/ACC Expert Consensus Document on Warfarin Therapy
JACC 2003;41:1633-52
American
Heart Association/American College of Cardiology Foundation
Guide to Warfarin Therapy
References
1.
Whitlon DS, Sadowski JA, Suttie JW. Mechanisms of coumarin
action: significance of vitamin K epoxide reductase inhibition.
Biochemistry 1978;17:1371–7.
2.
Fasco MJ, Hildebrandt EF, Suttie JW. Evidence that warfarin
anticoagulant action involves two distinct reductase activities.
J Biol Chem 1982;257:11210–2.
3. Choonara IA, Malia RG, Haynes BP, et al.
The relationship between inhibition of vitamin K1 2,3-epoxide
reductase and reduction of clotting factor activity with warfarin.
Br J Clin Pharmacol 1988;25:1–7.
4. Trivedi LS, Rhee M, Galivan JH, et al.
Normal and warfarin-resistant rat hepatocyte metabolism of
vitamin K 2,3 epoxide: evidence for multiple pathways of hydroxyvitamin
K formation. Arch Biochem Biophys 1988; 264:67–73.
5.
Stenflo J, Fernlund P, Egan W, et al. Vitamin K dependent
modifications of glutamic acid residues in prothrombin. Proc
Natl Acad Sci U S A 1974;71:2730 –3.
6. Nelsestuen GL, Zytkovicz TH, Howard JB.
The mode of action of vitamin K: identification of -carboxyglutamic
acid as a component of prothrombin. J Biol Chem 1974;249:6347–50.
7. Friedman PA, Rosenberg RD, Hauschka PV,
et al. A spectrum of partially carboxylated prothrombins in
the plasmas of coumarin treated patients. Biochim Biophys
Acta 1977;494:271– 6.
8. Malhotra OP, Nesheim ME, Mann KG. The kinetics
of activation of normal and gamma carboxy glutamic acid deficient
prothrombins. J Biol Chem 1985;260:279 – 87.
9. Nelsestuen GL. Role of -carboxyglutamic
acid: an unusual transition required for calcium-dependent
binding of prothrombin to phospholipid. J Biol Chem 1976;251:5648
–56.
10. Prendergast FG, Mann KG. Differentiation
of metal ion–induced transitions of prothrombin fragment
1. J Biol Chem 1977;252:840 –50.
11. Borowski M, Furie BC, Bauminger S, et
al. Prothrombin requires two sequential metal-dependent conformational
transitions to bind phospholipids: conformation-specific antibodies
directed against the phospholipid-binding site on prothrombin.
J Biol Chem 1986;261: 14969 –75.
12. Hauschka PV, Lian JB, Cole DEC, et al.
Osteocalcin and matrix Gla protein: vitamin K dependent proteins
in bone. Phys Rev 1989; 990 –1047.
13. Price PA. Role of vitamin K– dependent
proteins in bone metabolism. Annu Rev Nutr 1988;8:565–
83.
14. Maillard C, Berruyer M, Serre CM, et
al. Protein S, a vitamin K– pendent protein is a bone
matrix component synthesized and secreted osteoblasts. Endocrinology
1992;130:1599 – 604.
15. Pan LC, Williamson MK, Price PA. Sequence
of the precursor to bone -carboxyglutamic acid protein
that accumulated in treated osteosarcoma cells. J Biol Chem
1985;260:13398 – 401.
16. Pettifor JM, Benson R. Congenital malformations
associated with administration of oral anticoagulants during
pregnancy. J Pediatr 86:459 – 62.
17. Hall JG, Pauli RM, Wilson KM. Maternal
and fetal sequelae of agulation during pregnancy. Am J Med
1980;68:122– 40.
18. Breckenridge A. Oral anticoagulant drugs:
pharmacokinetic Semin Hematol 1978;15:19 –26.
19. O’Reilly RA. Vitamin K and other
oral anticoagulant drugs. Annu Med 1976;27:245– 61.
20. Kelly JG, O’Malley K. Clinical
pharmacokinetics of oral Clin Pharmacokinet 1979;4:1–15.
21. O’Reilly RA. Warfarin metabolism
and drug-drug interactions. Wessler S, Becker CG, Nemerson
Y, editors. The New Dimensions Warfarin Prophylaxis: Advances
in Experimental Medicine Biology. New York, NY: Plenum; 1986:205–12.
22. Miners JO, Birkett DJ. Cytochrome P4502C9:
an enzyme of importance in human drug metabolism. Brit J Clin
Pharmacol 525–38.
23. Aithal GP, Day CP, Kesteven PJ, et al.
Association of polymorphisms the cytochrome P450 CYP2C9 with
warfarin dose requirement and of bleeding complications. Lancet
1999;353:717–9.
24. Higashi M, Veenstra DL, Wittkowsky AK,
et al. Association CYP2C9 genetic variants and anticoagulation-related
outcomes warfarin therapy. JAMA 2002;287:1690 – 8.
25. Breckenridge A, Orme M, Wesseling H,
et al. Pharmacokinetics pharmacodynamics of the enantiomers
of warfarin in man. Pharmacol Ther 1974;15:424 –30.
26. O’Reilly RA. Studies on the optical
enantiomorphs of warfarin in Clin Pharmacol Ther 1974;16:348
–54.
27. O’Reilly RA, Trager WF. Stereoselective
interaction of with 13C/12C labelled racemates of warfarin
in man (abstr). Fed 1978;37:545.
28. Toon S, Low LK, Gibaldi M, et al. The
warfarin-sulfinpyrazone action: stereochemical considerations.
Clin Pharmacol Ther 15–24.
29. O’Reilly RA. The stereoselective
interaction of warfarin and dazole in man. N Engl J Med 1976;295:354
–7.
30. O’Reilly RA. Stereoselective interaction
of sulfamethoxazole with the separated enantiomorphs of racemic
in man. N Engl J Med 1980;302:33–5.
31. Lewis RJ, Trager WF, Chan KK, et al.
Warfarin: stereochemical of its metabolism and the interaction
with phenylbutazone. J Clin 1974;53:1607–17.
32. O’Reilly RA, Trager WF, Rettie
AE, et al. Interaction of with racemic warfarin and its separated
enantiomorphs in humans. Pharmacol Ther 1987;42:290 –
4.
33. O’Reilly RA. Lack of effect of
fortified wine ingested during fasting anticoagulant therapy.
Arch Intern Med 1981;141:458 –9.
34. Cropp JS, Bussey HI. A review of enzyme
induction of warfarin tabolism with recommendations for patient
management. therapy 1997;17:917–28.
35. O’Reilly RA, Pool JG, Aggeler PM.
Hereditary resistance to anticoagulant drugs in man and rat.
Ann N Y Acad Sci 913–31.
36. O’Reilly RA, Aggeler PM, Hoag MS,
et al. Hereditary transmission exceptional resistance to coumarin
anticoagulant drugs. N Engl J 1983;308:1229 –30.
37. Alving BM, Strickler MP, Knight RD,
et al. Hereditary warfarin tance: investigation of a rare
phenomenon. Arch Intern Med 499 –501.
38. Oldenburg J, Quenzel EM, Harbrecht U,
et al. Missense mutations ALA-10 in the factor IX propeptide:
an insignificant variant in life but a decisive cause of bleeding
during oral anticoagulant Br J Haematol 1997;98:240 –
4.
39. Chu K, Wu SM, Stanley T, et al. A mutation
in the propeptide of IX leads to warfarin sensitivity by a
novel mechanism. J Clin 1996;98:1619 –25.
40. Mannucci PM. Genetic control of anticoagulation.
Lancet 688 –9.
41. Gurwitz JH, Avorn J, Ross-Degnan D,
et al. Aging and the anticoagulant response to warfarin therapy.
Ann Intern Med 1992;116:901– 4.
42. Mungall D, White R. Aging and warfarin
therapy. Ann Intern Med 1992;117:878 –9.
43. Bowles SK. Stereoselective disposition
of warfarin in young and elderly subjects (abstr). Clin Pharmacol
Ther 1994;55:172.
44. O’Reilly R, Rytand D. “Resistance”
to warfarin due to unrecognized vitamin K supplementation.
N Engl J Med 1980;303:160 –1.
45. Suttie JW, Mummah-Schendel LL, Shah
DV, et al. Vitamin K deficiency from dietary vitamin K restriction
in humans. Am J Clin Nutr 1988;47:475– 80.
46. Sadowski JA, Booth SL, Mann KG, et al.
Structure and mechanism of activation of vitamin K antagonists.
In: Poller L, Hirsh J, editors. Oral Anticoagulants. London,
UK: Arnold; 1996:9 –29.
47. Bovill EG, Lawson J, Sadowski J, et
al. Mechanisms of vitamin K metabolism and vitamin K–
dependent hemostasis: implications for warfarin therapy. In:
Ezekowitz MD, editors. The Heart as a Source of Systemic Embolisation.
New York, NY: Marcel Dekker; 1992.
48. Booth SL, Charnley JM, Sadowski JA,
et al. Dietary vitamin K1 and stability of oral anticoagulation:
proposal of a diet with a constant vitamin K1 content. Thromb
Haemost 1997;77:504 –9.
49. Richards RK. Influence of fever upon
the action of 3,3-methylene bis-(4-hydroxoycoumarin). Science
1943;97:313– 6.
50. Owens JC, Neely WB, Owen WR. Effect
of sodium dextrothyroxine in patients receiving anticoagulants.
N Engl J Med 1962;266:76 –9.
51. Bechtold H, Andrassy K, Jahnchen E,
et al. Evidence for impaired hepatic vitamin K1 metabolism
in patients treated with N-methylthiotetrazole cephalosporins.
Thromb Haemost 1984;51:358 – 61.
52. Weitekamp MR, Aber RC. Prolonged bleeding
times and bleeding diathesis associated with moxalactam administration.
JAMA 1983;249: 69 –71.
53. O’Reilly RA, Sahud MA, Robinson
AJ. Studies on the interaction of warfarin and clofibrate
in man. Thromb Diath Haemorrh 1972;27: 309 –18.
54. Rothschild BM. Hematologic perturbations
associated with salicylate. Clin Pharmacol Ther 1979;26:145–52.
55. Hylek EM, Heiman H, Skates SJ, et al.
Acetaminophen and other risk factors for excessive warfarin
anticoagulation. JAMA 1998;279: 657– 62.
56. Bell WR. Acetaminophen and warfarin:
undesirable synergy. JAMA 1998;279:702–3.
57. Dale J, Myhre E, Loew D. Bleeding during
acetylsalicylic acid and anticoagulant therapy in patients
with reduced platelet reactivity after aortic valve replacement.
Am Heart J 1980;99:746 –52.
58. Schulman S, Henriksson K. Interaction
of ibuprofen and warfarin on primary haemostasis. Br J Rheumatol
1989;28:46 –9.
59. Cazenave J-P, Packham MA, Guccione MA,
et al. Effects of penicillin G on platelet aggregation, release
and adherence to collagen. Proc Soc Exp Med 1973;142:159 –
66.
60. Brown CH II, Natelson EA, Bradshaw W,
et al. The hemostatic defect produced by carbenicillin. N
Engl J Med 1974;291:265–70.
61. Roth GJ, Majerus PW. The mechanism of
the effect of aspirin on human platelets, I: acetylation of
a particulate fraction protein. J Clin Invest 1975;56:624
–32.
62. Chesebro JH, Fuster V, Elveback LR,
et al. Trial of combined warfarin plus dipyridamole or aspirin
therapy in prosthetic heart valve replacement: danger of aspirin
compared with dipyridamole. Am J Cardiol 1983;51:1537–
41.
63. Turpie AG, Gent M, Laupacis A, et al.
A comparison of aspirin with placebo in patients treated with
warfarin after heart-valve replacement. N Engl J Med 1993;329:524
–9.
64. The Medical Research Council’s
General Practice Research Framework. Thrombosis prevention
trial: randomised trial of low-intensity oral anticoagulation
with warfarin and low-dose aspirin in the primary prevention
is ischaemic heart disease in men at increased risk. Lancet
1998;351:233– 41.
65. Weibert RT, Lorentz SM, Townsend RJ,
et al. Effect of erythromycin in patients receiving long-term
warfarin therapy. Clin Pharm 1989;8: 210 –24.
66. Lorentz SM, Weibert RT. Potentiation
of warfarin anticoagulation by topical testosterone treatment.
Clin Pharm 1985;4:332– 4.
67. Udall JA. Human sources and absorption
of vitamin K in relation to anticoagulation stability. JAMA
1965;194:127–9.
68. Wells PS, Holbrook AM, Crowther NR,
et al. The interaction of warfarin with drugs and food: a
critical review of the literature. Ann Intern Med 1994;121:676
– 83.
69. Koch-Weser J, Sellers EM. Drug interactions
with oral anticoagulants. N Engl J Med 1971;285:487–98.
70. Sellers E, Weser JK. Drug interactions
with coumarin anticoagulants. N Engl J Med 1971;285:547–58.
71. Wittkowsky AK. Drug interactions updates:
drugs, herbs and oral anticoagulation. J Thromb Thrombolysis
2001;12:67–71.
72. Wessler S, Gitel SN. Warfarin: from bedside
to bench. N Engl J Med 1984;311:645–52.
73. Zivelin A, Rao LV, Rapaport SI. Mechanism
of the anticoagulant effect of warfarin as evaluated in rabbits
by selective depression of individual procoagulant vitamin-K
dependent clotting factors. J Clin Invest 1993; 92:2131–
40.
74. Patel P, Weitz J, Brooker LA, et al.
Decreased thrombin activity of fibrin clots prepared in cord
plasma compared to adult plasma. Pediatr Res 1996;39:826 –30.
75. Weitz JI, Hudoba M, Massel D, et al.
Clot-bound thrombin is protected from inhibition by heparin-antithrombin
III but is susceptible to inactivation by antithrombin III–independent
inhibitors. J Clin Invest 1990; 86:385–91.
76. Furie B, Diuguid CF, Jacobs M, et al.
Randomized prospective trial comparing the native prothrombin
antigen with the prothrombin time for monitoring anticoagulant
therapy. Blood 1990;75:344 –9.
77. Harrison L, Johnston M, Massicotte MP,
et al. Comparison of 5-mg and 10-mg loading doses in initiation
of warfarin therapy. Ann Intern Med 1997;126:133– 6.
78. Quick AJ. The prothrombin time in haemophilia
and in obstructive jaundice. J Biol Chem 1935;109:73–
4.
79. Zucker S, Cathey MH, Sox PJ, et al.
Standardization of laboratory tests for controlling anticoagulant
therapy. Am J Clin Pathol 1970;53: 348 –54.
80. Poller L. Progress in standardisation
in anticoagulant control. Hematol Rev 1987;1:225– 41.
81. Latallo ZS, Thomson JM, Poller L. An
evaluation of chromogenic substrates in the control of oral
anticoagulant therapy. Br J Haematol 1981;47:307–18.
82. Poller L, Taberner DA. Dosage and control
of oral anticoagulants: an international survey. Br J Haematol
1982;51:479 – 85.
83. Kirkwood TBL. Calibration of reference
thromboplastins and standardisation of the prothrombin time
ratio. Thromb Haemost 1983;49: 238 – 44.
84. Bussey HI, Force RW, Bianco TM, et al.
Reliance on prothrombin time ratios causes significant errors
in anticoagulation therapy. Arch Intern Med 1992;152:278 –
82.
85. Tripodi A, Chantarangkul V, Braga M,
et al. Results of a multicenter study assessing the status
of a recombinant thromboplastin for the control of oral anticoagulant
therapy. Thromb Haemost 1994;72:261–7.
86. Hirsh J. Is the dose of warfarin prescribed
by American physicians unnecessarily high? Arch Intern Med
1987;147:769 –71.
87. World Health Organization Expert Committee
on Biological Standardization. 33rd Report Technical Report
Series No. 687. Geneva: World Health Organization; 1983.
88. Johnston M, Harrison L, Moffat K, et
al. Reliability of the international normalized ratio for
monitoring the induction phase of warfarin: comparison with
the prothrombin time ratio. J Lab Clin Med 1996;128: 214 –7.
89. Kovacs MJ, Wong A, MacKinnon K, et al.
Assessment of the validity of the INR system for patients
with liver impairment. Thromb Haemost 1994;71:727–30.
90. College of American Pathologists Coagulation
Survey Set: CG2-C. Northfield, IL: College of American Pathologists;
1997.
91. Taberner DA, Poller L, Thomson JM, et
al. Effect of international sensitivity index (ISI) of thromboplastins
on precision of international normalized ratios (INR). J Clin
Pathol 1989;42:92– 6.
92. Poller L, Hirsh J. Laboratory monitoring
of anticoagulants. In: Poller L, Hirsh J, editors. Oral Anticoagulants.
London, UK: Arnold; 1996: 49 – 64.
93. Brien WF, Crawford L, Wood DE. Discrepant
results in INR testing. Thromb Haemost 1994;72:986 –7.
94. van den Besselaar AM, Evatt BL, Brogan
DR, et al. Proficiency testing and standardization of prothrombin
time: effect of thromboplastin, instrumentation, and plasma.
Am J Clin Pathol 1984;82:688 –99.
95. Poller L, Triplett DA, Hirsh J, et al.
The value of plasma calibrants in correcting coagulometer
effects on international normalized ratios: an international
multicenter study. Am J Clin Pathol 1995;103:358 – 65.
96. Poller L, Thomson JM, Taberner DA, et
al. The correction of coagulometer effects on international
normalized ratios: a multicentre evaluation. Br J Haematol
1994;86:112–7.
97. Poller L, Triplett DA, Hirsh J, et al.
A comparison of lyophilized artificially depleted plasma and
lyophilized plasma from warfarin treated in correcting for
coagulometer effects on international normalized ratios.
Am J Clin Pathol 1995;103:366 –71.
98. Poggio M, van den Besselaar AM, van
der Velde EA, et al. The effect of some instruments for prothrombin
time testing on the International Sensitivity Index (ISI)
of two rabbit tissue thromboplastin reagents. Thromb Haemost
1989;62:868 –74.
99. D’Angelo A, Seveso MP, D’Angelo
SV, et al. Comparison of two automated coagulometers and the
manual tilt tube method for determination of prothrombin time.
Am J Clin Pathol 1989;92:321– 8.
100. Poller L, Thomson JM, Taberner DA.
Effect of automation on the prothrombin time test in NEQAS
surveys. J Clin Pathol 1989;42: 97–100.
101. Ray MJ, Smith IR. The dependence of
the International Sensitivity Index on the coagulometer used
to perform the prothrombin time. Thromb Haemost 1990;63:424
–9.
102. van Rijn JL, Schmidt NA, Rutten WP.
Correction of instrument and reagent based differences in
determination of the International Normalised Ratio (INR)
for monitoring anticoagulant therapy. Clin Chem 1989;35:840
–3.
103. Thomson JM, Taberner DA, Poller L.
Automation and prothrombin time: a United Kingdom field study
of two widely used coagulometers. J Clin Pathol 1990;43:679
– 84.
104. Fairweather RB, Ansell J, van den
Besselaar AM, et al. Laboratory monitoring of oral anticoagulant
therapy: College of American Pathologists Conference XXXI
on laboratory monitoring of anticoagulant therapy. Arch Pathol
Lab Med 1998;122:768 – 81.
105. Ng VL, Levin J, Corash L, et al. Failure
of the International Normalized Ratio to generate consistent
results within a local medical community. Am J Clin Pathol
1993;99:689 –94.
106. Poller L. Laboratory control of oral
anticoagulants. Br Med J 1987; 294:1184.
107. Kazama M, Suzuki S, Abe T, et al. Evaluation of international
normalized ratios by a controlled field survey with 4 different
thromboplastin reagents. Thromb Haemost 1990;64:535–
41.
108. van den Besselaar AM, Lewis SM, Mannucci
PM, et al. Status of present and candidate International Reference
Preparations (IRP) of thromboplastin for the prothrombin
time: a report of the Subcommittee for Control of Anticoagulation.
Thromb Haemost 1993;69:85.
109. Duncan EM, Casey CR, Duncan BM, et al. Effect of concentration
of trisodium citrate anticoagulant on calculation of the international
normalized ratio and the international sensitivity index
of thromboplastin. Thromb Haemost 1994;72:84 – 8.
110. Adcock DM, Kressen DC, Marlar RA.
Effect of 3.2% vs 3.8% sodium citrate on routine coagulation
testing. Am J Clin Pathol 1997;107: 105–10.
111. Moll S, Ortel TL. Monitoring warfarin
therapy in patients with lupus anticoagulants. Ann Intern
Med 1997;127:177– 85.
112. Della Valle P, Crippa L, Safa O, et
al. Potential failure of the International Normalized Ratio
(INR) system in the monitoring of oral anticoagulation in
patients with lupus anticoagulants. Ann Med Interne (Paris)
1996;147 Suppl:10 – 4.
113. Rapaport SI, Le DT. Thrombosis in
the antiphospholipid antibody syndrome. N Engl J Med 1995;333:665.
114. Le DT, Weibert RT, Sevilla BK, et
al. The international normalized ratio (INR) for monitoring
warfarin therapy: reliability and relation to other monitoring
methods. Ann Intern Med 1994;120:552– 8.
115. Lind SE, Callas PW, Golden EA, et
al. Plasma levels of factors II, VII, and X and their relationship
to the International Normalized Ratio during chronic warfarin
therapy. Blood Coagul Fibrinolysis 1997;8: 48 –53.
116. Kornberg A, Francis CW, Pellegrini
VD Jr, et al. Comparison of native prothrombin antigen with
the prothrombin time for monitoring oral anticoagulant prophylaxis.
Circulation 1993;88:454 – 60.
117. James AH, Britt RP, Raskino CL, et
al. Factors affecting the maintenance dose of warfarin.
J Clin Pathol 1992;45:704 – 6.
118. Hylek EM, Singer DE. Risk factors
for intracranial hemorrhage in outpatients taking warfarin.
Ann Intern Med 1994;120:897–902.
119. ASPECT Research Group. Effect of long-term
oral anticoagulant treatment on mortality and cardiovascular
morbidity after myocardial infarction. Lancet 1994;343:499
–503.
120. Cannegieter SC, Rosendaal FR, Wintzen
AR, et al. Optimal oral anticoagulant therapy in patients
with mechanical heart valve prostheses: the Leiden artificial
valve and anticoagulation study. N Engl J Med 1995; 333:11–7.
121. Stroke Prevention in Reversible Ischemia
Trial (SPIRIT) Study Group. A randomized trial of anticoagulants
versus aspirin after cerebral ischemia of presumed arterial
origin. Ann Neurol 1997;42:857– 65.
122. Mohr JP, Thompson JLP, Lazar RM, et
al. A comparison of warfarin and aspirin for the prevention
of recurrent ischemic stroke. N Engl J Med 2001;345:1444 –51.
123. Hylek EM, Skates SJ, Sheehan MA, et
al. An analysis of the lowest effective intensity of prophylactic
anticoagulation for patients with nonrheumatic atrial fibrillation.
N Engl J Med 1996;335:540 – 6.
124. Stroke Prevention in Atrial Fibrillation
Investigators. Adjusted-dose warfarin versus low-intensity,
fixed-dose warfarin plus aspirin for high-risk patients with
atrial fibrillation: Stroke Prevention in Atrial Fibrillation
III randomised clinical trial. Lancet 1996;348:633–
8.
125. Lucas FV, Duncan A, Jay R, et al.
A novel whole blood capillary technique for measuring prothrombin
time. Am J Clin Pathol 1987;88: 442– 6.
126. Yano Y, Kambayashi J, Murata K, et
al. Bedside monitoring of warfarin therapy by a whole blood
capillary coagulation monitor. Thromb Res 1992;66:583–90.
127. Leaning KE, Ansell JE. Advances in
the monitoring of oral anticoagulation: point-of-care testing,
patient self-monitoring, and patient selfmanagement. J Thromb
Thrombolysis 1996;3:377– 83.
128. Jennings I, Luddington RJ, Baglin
T. Evaluation of the Ciba Corning Biotrack 512 coagulation
monitor for the control of oral anticoagulation. J Clin Pathol
1991;44:950 –3.
129. McCurdy SA, White RH. Accuracy and
precision of a portable anticoagulation monitor in a clinical
setting. Arch Intern Med 1992;152: 589 –92.
130. Tripodi A, Arbini AA, Chantarangkul
V, et al. Are capillary whole blood coagulation monitors suitable
for the control of oral anticoagulant treatment by the international
normalized ratio? Thromb Haemost 1993; 70:921– 4.
131. Oberhardt BJ, Dermott SC, Taylor M,
et al. Dry reagent technology for rapid, convenient measurements
of blood coagulation and fibrinolysis. Clin Chem 1991;37:520
– 6.
132. Rose VL, Dermott SC, Murray BF, et
al. Decentralized testing for prothrombin time and activated
partial thromboplastin time using a dry chemistry portable
analyzer. Arch Pathol Lab Med 1993;117:611–7.
133. Fabbrini N, Messmore H, Balbale S,
et al. Pilot study to determine use of a TAS analyzer in an
anticoagulation clinic setting (abstr). Blood 1995;86 Suppl:869a.
134. Tripodi A, Chantarangkul V, Clerici
M, et al. Determination of the International Sensitivity Index
of a new near-patient testing device to monitor oral anticoagulant
therapy– overview of the assessment of conformity
to the calibration model. Thromb Haemost 1997;78:855–
8.
135. Kaatz AA, White RH, Hill J, et al.
Accuracy of laboratory and portable monitor international
normalized ratio determinations: comparison with a criterion
standard. Arch Intern Med 1995;155:1861–7.
136. Ansell J, Becker D, Andrew M, et al.
Accurate and precise prothrombin time measurement in a multicenter
anticoagulation trial employing patient self-testing (abstr).
Blood 1995;86 Suppl:864a.
137. Andrew M, Marzinotto V, Adams M, et
al. Monitoring of oral anticoagulant therapy in pediatric
patients using a new microsample PT device. Blood 1995;86
Suppl:863a.
138. Ansell JE, Zweig S, Meyer B, et al.
Performance of the AvocetPT prothrombin time system (abstr).
Blood 1998;92 Suppl:112b.
139. Anderson DR, Harrison L, Hirsh J.
Evaluation of a portable prothrombin time monitor for home
use by patients who require long-term oral anticoagulant therapy.
Arch Intern Med 1993;153:1441–7.
140. White RH, McCurdy SA, von Marensdorff
H, et al. Home prothrombin time monitoring after the initiation
of warfarin therapy: a randomized, prospective study. Ann
Intern Med 1989;111:730 –7.
141. Beyth RJ, Landefeld CS. Prevention
of major bleeding in older patients treated with warfarin:
results of a randomized trial (abstr). J Gen Intern Med 1997;12:66.
142. Hasenkam JM, Knudsen L, Kimose HH,
et al. Practicability of patient self-testing of oral anticoagulant
therapy by the international normalized ?ratio (INR) using
a portable whole blood monitor: a pilot investigation. Thromb
Res 1997;85:77– 82.
143. Erdman S, Vidne B, Levy MJ. A self-control
method for long-term anticoagulation therapy. J Cardiovasc
Surg 1974;15:454 –7.
144. Ansell J, Holden A, Knapic N. Patient
self-management of oral anticoagulation guided by capillary
(fingerstick) whole blood prothrombin times. Arch Intern Med
1989;149:2509 –11.
145. Ansell J, Patel N, Ostrovsky D, et
al. Long-term patient selfmanagement of oral anticoagulation.
Arch Intern Med 1995;155: 2185–9. 146. Bernardo A. Experience
with patient self-management of oral anticoagulation. J
Thromb Thrombolysis 1996;2:321–5.
147.Horstkotte D, Piper C, Wiemer M, et
al. Improvement of prognosis by home prothrombin estimation
in patients with life-long anticoagulant therapy (abstr).
Eur Heart J 1996;17 Suppl:230.
148. Sawicki PT, Working Group for the
Study of Patient Self-Management of Oral Anticoagulation.
A structured teaching and self-management program for patients
receiving oral anticoagulation: a randomized controlled
trial. JAMA 1999;281:145–50.
149. Kortke H, Korfer R. International normalized
ratio self-management after mechanical heart valve replacement:
is an early start advantageous Ann Thorac Surg 2001;72:44
– 8.
150. Watzke HH, Forberg E, Svolba G, et
al. A prospective controlled trial comparing weekly self-testing
and self-dosing with the standard management of patients
on stable oral anticoagulation. Thromb Haemost 2000;83:661–5.
151. Cromheecke ME, Levi M, Colly LP, et
al. Oral anticoagulation selfmanagement and management by
a specialist anticoagulation clinic: a randomized cross-over
comparison. Lancet 2000;356:97–102.
152. Gadisseur AP, Breukink-Engbers WG,
van der Meer FJ, et al. Comparison of the quality of oral
anticoagulation therapy through patient self-management versus
management by specialized anticoagulation clinics in the Netherlands
(abstr). Thromb Haemost 2001;86 Suppl: OC161.
153. Kaatz S, Elston-Lafata J, Gooldy S.
Anticoagulation therapy home and office evaluation (AT HOME)
study (abstr). Thromb Haemost 2001;86 Suppl:P779.
154. Wilson R, James AH. Computer assisted
management of warfarin treatment. Br Med J 1984;289:422–
4.
155. White RH, Mungall D. Outpatient management
of warfarin therapy: comparison of computer-predicted dosage
adjustment to skilled professional care. Ther Drug Monit
1991;13:46 –50.
156. Poller L, Shiach CR, MacCallum
PK, et al. Multicentre randomised study of computerised anticoagulant
dosage: European Concerted Action on Anticoagulation. Lancet
1998;352:1505–9.
157. Poller L, Wright D, Rowlands M. Prospective
comparative study of computer programs used for management
of warfarin. J Clin Pathol 1993;46:299 –303.
158. Ageno W, Turpie AGG. A randomized
comparison of a computer-based dosing program with a manual
system to monitor oral anticoagulant therapy. Thromb Res 1998;91:237–
40.
159. White RH, McKittrick T, Hutchinson
R, et al. Temporary discontinuation of warfarin therapy:
changes in the international normalized ratio. Ann Intern
Med 1995;122:40 –2.
160. Crowther MA, Julian J, McCarty D,
et al. Treatment of warfarinassociated coagulopathy with
oral vitamin K: a randomised controlled trial. Lancet 2000;356:1551–3.
161. Whitling AM, Bussey HI, Lyons RM.
Comparing different routes and doses of phytonadione for reversing
excessive anticoagulation. Arch Intern Med 1998;158:2136 –
40.
162. Crowther MA, Douketis JD, Schnurr
T, et al. Oral vitamin K lowers the international normalized
ratio more rapidly than subcutaneous vitamin K in the treatment
of warfarin-associated coagulopathy: a randomized, controlled
trial. Ann Intern Med 2002;137:251– 4.
163. Park BK, Scott AK, Wilson AC, et al.
Plasma disposition of vitamin K1 in relation to anticoagulant
poisoning. Br J Clin Pharmacol 1984;18: 655– 62.
164. Ansell J, Hirsh J, Dalen J, et al.
Managing oral anticoagulant therapy. Chest 2001;119 Suppl:22S–38S.
165. Landefeld CS, Goldman L. Major bleeding
in outpatients treated with warfarin: incidence and prediction
by factors known at the start of outpatient therapy. Am J
Med 1989;87:144 –52.
166. Landefeld CS, Rosenblatt MW. Bleeding
in outpatients treated with warfarin: relation to the prothrombin
time and important remediable lesions. Am J Med 1989;87:153–9.
167. Hull R, Hirsh J, Jay R, et al. Different
intensities of oral anticoagulant therapy in the treatment
of proximal-vein thrombosis. N Engl J Med 1982;307:1676 –
81.
168. Turpie AGG, Gunstensen J, Hirsh J,
et al. Randomized comparison of two intensities of oral anticoagulant
therapy after tissue heart valve replacement. Lancet 1988;1:1242–5.
169. Saour JN, Sieck JO, Mamo LAR, et al.
Trial of different intensities of anticoagulation in patients
with prosthetic heart valves. N Engl J Med 1990;322:428 –32.
170. Altman R, Rouvier J, Gurfinkel E,
et al. Comparison of two levels of anticoagulant therapy in
patients with substitute heart valves. J Thorac Cardiovasc
Surg 1991;101:427–31.
171. Levine MN, Raskob G, Landefeld S,
et al. Hemorrhagic complications of anticoagulant treatment.
Chest 1995;108 Suppl:276s–90s.
172. Beyth RJ, Quinn LM, Landefeld CS.
Prospective evaluation of an index for predicting the risk
of major bleeding in outpatients treated with warfarin. Am
J Med 1998;105:91–9.
173. Hart RG, Halperin JL. Atrial fibrillation
and thromboembolism: a decade of progress in stroke prevention.
Ann Intern Med 1999;131: 688 –95.
174. Kearon C, Hirsh J. Management of anticoagulation
before and after elective surgery. N Engl J Med 1997;336:1506
–11.
175. Sindet-Pedersen S, Ramstrom G, Bernvil
S, et al. Hemostatic effect of tranexamic acid mouthwash in
anticoagulant-treated patients undergoing oral surgery. N
Engl J Med 1989;320:840 –3.
176. Souto JC, Oliver A, ZuaZu-Jausoro
I, et al. Oral surgery in anticoagulated patients without
reducing the dose of oral anticoagulant: a prospective randomized
study. J Oral Maxillofac Surg 1996;54:27–32.
177. Sbarouni E, Oakley CM. Outcome of
pregnancy in women with valve prostheses. Br Heart J 1994;71:196
–201.
178. Hanania G. Management of anticoagulants
during pregnancy. Heart 2001;86:125– 6.
179. Montalescot G, Polle V, Collet JP,
et al. Low molecular weight heparin after mechanical heart
valve replacement. Circulation 2000;101:1083– 6.
180. McKenna R, Cole ER, Vasan U. Is warfarin
sodium contraindicated in the lactating mother J Pediatr 1983;103:325–7.
181. Lao TT, de Swiet M, Letsky E, et al.
Prophylaxis of thromboembolism in pregnancy: an alternative.
Br J Obstet Gynecol 1985;92:202– 6.
182. Verhagen H. Local hemorrhage and necrosis
of the skin and underlying tissues at starting therapy with
dicumarol or dicumacyl. Acta Med Scand 1954;148:455–
67.
183. Weinberg AC, Lieskovsky G, McGehee
WG, et al. Warfarin necrosis of the skin and subcutaneous
tissue of the male genitalia. J Urol 1983;130: 352–
4.
184. Broekmans AW, Bertina RM, Loeliger
EA, et al. Protein C and the development of skin necrosis
during anticoagulant therapy. Thromb Haemost 1983;49:244 –51.
185. Zauber NP, Stark MW. Successful warfarin
anticoagulation despite protein C deficiency and a history
of warfarin necrosis. Ann Intern Med 1986;104:659 –
60.
186. Samama M, Horellou MH, Soria J, et
al. Successful progressive anticoagulation in a severe protein
C deficiency and previous skin necrosis at the initiation
of oral anticoagulation treatment. Thromb Haemost 1984;51:332–3.
187. Grimaudo V, Gueissaz F, Hauert J,
et al. Necrosis of skin induced by coumarin in a patient deficient
in protein S. BMJ 1989;298:233– 4.
187a. Mohr JP, Thompson JLP, Lazar RM,
et al. A comparison of warfarin and aspirin for the prevention
of recurrent ischemic stroke. N Engl J Med 2001;345:1444 –51.
188. Sevitt S, Gallagher NG. Prevention
of venous thrombosis and pulmonary embolism in injured patients.
Lancet 1959;II:981–9.
189. Francis CW, Marder VJ, Evarts CM,
et al. Two-step warfarin therapy: prevention of postoperative
venous thrombosis without excessive bleeding. JAMA 1983;249:374
– 8.
190. Powers PJ, Gent M, Jay RM, et al.
A randomized trial of less intense postoperative warfarin
or aspirin therapy in the prevention of venous thromboembolism
after surgery for fractured hip. Arch Intern Med 1989;149:771–
4.
191. Taberner DA, Poller L, Burslem RW,
et al. Oral anticoagulants controlled by the British comparative
thromboplastin versus low-dose heparin in prophylaxis of deep
vein thrombosis. BMJ 1978;1:272– 4.
192. Poller L, McKernan A, Thomson JM,
et al. Fixed minidose warfarin: a new approach to prophylaxis
against venous thrombosis after major surgery. Br Med J 1987;295:1309
–12.
193. Bern MM, Lokich JJ, Wallach SR, et
al. Very low doses of warfarin can prevent thrombosis in central
venous catheters: a randomized prospective trial. Ann Intern
Med 1990;112:423– 8.
194. Poller L, MacCallum PK, Thomson JM,
et al. Reduction of factor VII coagulant activity (VIIC),
a risk factor for ischaemic heart disease, by fixed dose warfarin:
a double blind crossover study. Br Heart J 1990; 63:231–3.
195. Dale C, Gallus A, Wycherley A, et
al. Prevention of venous thrombosis with minidose warfarin
after joint replacement. BMJ 1991;303:224.
196. Fordyce MJF, Baker AS, Staddon GE.
Efficacy of fixed minidose warfarin prophylaxis in total hip
replacement. BMJ 1991;303:219 –20.
197. Poller L, Thomson JM, MacCallum PK,
et al. Minidose warfarin and failure to prevent deep vein
thrombosis after joint replacement surgery despite inhibiting
the postoperative rise in plasminogen activator inhibitor
activity. Clin Appl Thromb Hemost 1995;1:267–73.
198. Levine M, Hirsh J, Gent M, et al.
Double-blind randomised trial of a very-low-dose warfarin
for prevention of thromboembolism in stage IV breast cancer.
Lancet 1994;343:886 –9.
199. Hirsh J. The optimal duration of anticoagulant
therapy for venous thrombosis. N Engl J Med 1995;332:1710
–11.
200. Hirsh J, Lee A. How we diagnose and
treat deep vein thrombosis. Blood 2002;99:3102–10.
201. Hull R, Delmore T, Genton E, et al.
Warfarin sodium versus low-dose heparin in the long-term treatment
of venous thrombosis. N Engl J Med 1979;301:855– 8.
202. Hull R, Delmore T, Carter C, et al.
Adjusted subcutaneous heparin versus warfarin sodium in the
long-term treatment of venous thrombosis. N Engl J Med 1982;306:189
–94.
203.
Lagerstedt CI, Fagher BO, Albrechtsson U, et al. Need for
long-term anticoagulant treatment in symptomatic calf-vein
thrombosis. Lancet 1985;2:515– 8.
204. Schulman S, Rhedin A, Lindmarker P,
et al. A comparison of six weeks with six months of oral anticoagulant
therapy after a first episode of venous thromboembolism. N
Engl J Med 1995;332:1661–5.
205. Schulman S, Granqvist S, Holmstrom
M, et al. The duration of oral anticoagulant therapy after
a second episode of venous thromboembolism: Duration of
Anticoagulation Trial Study Group. N Engl J Med 1997;336:393–
8.
206. Schulman S, Svenungsson E, Granqvist
S. Anticardiolipin antibodies predict early recurrence of
thromboembolism and death among patients with venous thromboembolism
following anticoagulant therapy: Duration of Anticoagulation
Study Group. Am J Med 1998;104:332– 8.
207. Simioni P, Prandoni P, Zanon E, et
al. Deep venous thrombosis and lupus anticoagulant: a case-control
study. Thromb Haemost 1996;76: 187–9.
208. Rance A, Emmerich J, Fiessinger JN.
Anticardiolipin antibodies and recurrent thromboembolism.
Thromb Haemost 1997;77:221–2.
209. Kearon C, Gent M, Hirsh J, et al.
A comparison of three months of anticoagulation with extended
anticoagulation for a first episode of idiopathic venous thromboembolism.
N Engl J Med 1999;340:901–7.
210. Coumadin Aspirin Reinfarction Study
(CARS) Investigators. Randomised double-blind trial of fixed
low-dose warfarin with aspirin after myocardial infarction.
Lancet 1997;350:389 –96.
211. The Post Coronary Artery Bypass Graft
Trial Investigators. The effect of aggressive lowering of
low-density lipoprotein cholesterol levels and low-dose anticoagulation
on obstructive changes in saphenous-vein coronary-artery
bypass grafts. N Engl J Med 1997;336:153– 62.
212. Veterans Administration Cooperative
Study. Anticoagulants in acute myocardial infarction: results
of a cooperative clinical trial. JAMA 1973;225:724 –9.
213. Drapkin A, Merskey C. Anticoagulant
therapy after acute myocardial infarction: relation of therapeutic
benefit to patient’s age, sex, and severity of infarction.
JAMA 1972;222:541– 8.
214. Medical Research Council Group. Assessment
of short-term anticoagulant administration after cardiac
infarction: report of the Working Party on Anticoagulant Therapy
in Coronary Thrombosis. BMJ 1969; 1:335– 42.
215. Cairns JA, Hirsh J, Lewis HD Jr, et
al. Antithrombotic agents in coronary artery disease. Chest
1992;102 Suppl:456s– 81s.
216. Goldberg RJ, Gore JM, Dalen JE, et
al. Long-term anticoagulant therapy after acute myocardial
infarction. Am Heart J 1985;109:616 –22.
217. Leizorovicz A, Boissel JP. Oral anticoagulant
in patients surviving myocardial infarction: a new approach
to old data. Eur J Clin Pharmacol 1983;24:333– 6.
218. Sixty-Plus Reinfarction Study Group.
A double-blind trial to assess long-term oral anticoagulant
therapy in elderly patients after myocardial infarction. Lancet
1980;2:989 –94.
219. Smith P, Arnesen H, Holme I. The effect
of warfarin on mortality and reinfarction after myocardial
infarction. N Engl J Med 1990;323: 147–52.
220. van Es RF. Anticoagulants in the Secondary
Prevention of Events in Coronary Thrombosis-2. Abstract presented
at the 22nd meeting of the European Society of Cardiology,
Amsterdam, 2000. Available at: http:// www.cardiosource.com/trials/trial?searchtocA&publishedn&uid?
MDTRIALS.42057.
221. Brower MA. Antithrombotics in the
Prevention of Reocclusion In Coronary Thrombolysis-2. Abstract
presented at the 22nd meeting of the European Society of Cardiology,
Amsterdam, 2000. Available at: http:// www.cardiosource.com/trials/trial?searchtocA&publishedn&uid?
MDTRIALS.32678.
222. Hurlen M, Smith P, Abdelnoor M, et
al. Warfarin Aspirin Reinfarction Study II: Effects of warfarin,
aspirin and the two combined, on mortality and thromboembolic
morbidity after myocardial infarction. Abstract presented
at the 23rd meeting of the European Society of Cardiology,
Stockholm, 2001. Available at: http://www.escardio.org/congress/
Stock01/hotline/slides/WARIS%20II%20Press.pdf.
223. Fiore LD, Ezekowitz MD, Brophy Mt,
et al. Department of Veterans Affairs Cooperative Program
Clinical Trial comparing combined warfarin and aspirin with
aspirin alone in survivors of acute myocardial infarction:
primary results of the CHAMP study. Circulation 2002;105:
557– 63.
224. Kretschmer G, Wenzl E, Schemper M,
et al. Influence of postoperative anticoagulant treatment
on patient survival after femoropopliteal vein bypass surgery.
Lancet 1988;1:797– 8.
225. Anand SS, Yusuf S. Oral anticoagulant
therapy in patients with coronary artery disease: a meta-analysis.
JAMA 1999;282:2058 – 67.
226. Theroux P, Waters D, Lam J, et al.
Reactivation of unstable angina following discontinuation
of heparin. N Engl J Med 1992;327:141–5.
227. The FRISC Study Group. Low-molecular-weight
heparin during instability in coronary artery disease. Lancet
1996;347:561– 8.
228. Cohen M, Théroux P, Weber S,
et al. Combination therapy with tirofiban and enoxaparin in
acute coronary syndromes. Int J Cardiol 1999;71:273–
81.
229. Williams DO, Kirby MG, McPherson K,
et al. Anticoagulant treatment in unstable angina. Br J Clin
Pract 1986;40:114 – 6.
230. Cohen M, Adams PC, Parry G, et al.
Combination antithrombotic therapy in unstable rest angina
and non–Q-wave infarction in nonprior aspirin users:
primary end point analysis from the ATACS trial. Circulation
1994;89:81– 8.
231. Anand SS, Yusuf S, Pogue J, et al.
Long-term oral anticoagulant therapy in patients with unstable
angina or suspected non–Q-wave myocardial infarction:
Organization to Assess Strategies for Ischemic Syndromes (OASIS)
pilot study results. Circulation 1998;98:1064 –70.
232. Mok CK, Boey J, Wang R, et al. Warfarin
versus dipyridamole-aspirin and pentoxifylline-aspirin for
the prevention of prosthetic heart valve thromboembolism:
a prospective clinical trial. Circulation 1985;72: 1059 –
63.
233. Gohlke-Barwolf, Acar J, Oakley C,
et al. Guidelines for prevention of thromboembolic events
in valvular heart disease: Study Group of the Working Group
on Valvular Heart Disease of the European Society of Cardiology.
Eur Heart J 1995;16:1320 –30.
234. Stein PD, Alpert JS, Dalen JE, et
al. Antithrombotic therapy in patients with mechanical and
biological prosthetic heart valves. Chest 1998;114 Suppl:602S–10S.
235. ACC/AHA guidelines for the management
of patients with valvular heart disease: a report of the American
College of Cardiology/American Heart Association Task Force
on Practice Guidelines (Committee on ?Management of Patients
with Valvular Heart Disease). J Am Coll Cardiol 1998;32:1486
–588.
236. Vongpatanasin W, Hillis LD, Lange
RA. Prosthetic heart valves. N Engl J Med 1996;335:407–16.
237. The Stroke Prevention in Atrial Fibrillation
Investigators. The stroke prevention in atrial fibrillation
study: final results. Circulation 1991;84: 527–39.
238. The Boston Area Anticoagulation Trial
for Atrial Fibrillation Investigators. The effect of low-dose
warfarin on the risk of stroke in patients with nonrheumatic
atrial fibrillation. N Engl J Med 1990;323:1505–11.
239. Ezekowitz MD, Bridgers SL, James KE,
et al. Warfarin in the prevention of stroke associated with
nonrheumatic atrial fibrillation: Veterans Affairs Stroke
Prevention in Nonrheumatic Atrial Fibrillation Investigators.
N Engl J Med 1992;327:1406 –12.
240. Petersen P, Boysen G, Godtfredsen
J, et al. Placebo-controlled, randomised trial of warfarin
and aspirin for prevention of thromboembolic complications
in chronic atrial fibrillation: the Copenhagen AFASAK Study.
Lancet 1989;1:175–9.
241. Connolly SJ, Laupacis A, Gent M, et
al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study.
J Am Coll Cardiol 1991;18:349 –55.
242.
Atrial Fibrillation Investigators. Risk factors for stroke
and efficacy of antithrombotic therapy in atrial fibrillation:
analysis of pooled data from five randomized controlled trials.
Arch Intern Med 1994;154:1449 –57.
243. Albers GW, Sherman DG, Gress DR, et
al. Stroke prevention in nonvalvular atrial fibrillation:
a review of prospective randomized trials. Ann Neurol 1991;30:511–
8.
244. Atwood J, Albers G. Anticoagulation
and atrial fibrillation. Herz 1993; 18:27–38.
245.
European Atrial Fibrillation Trial Study Group. Secondary
prevention in non-rheumatic atrial fibrillation after transient
ischaemic attack or minor stroke. Lancet 1993;342:1255–
62.
246. Stroke Prevention in Atrial Fibrillation
Investigators. Warfarin versus aspirin for prevention of thromboembolism
in atrial fibrillation: Stroke Prevention in Atrial Fibrillation
II Study. Lancet 1994;343:687–91.
247. Hellemons BS, Langenberg M, Lodder
J, et al. Primary prevention of arterial thromboembolism in
non-rheumatic atrial fibrillation in primary care: randomised
controlled trial comparing two intensities of coumarin with
aspirin. BMJ 1999;319:958 – 64.
248. Fuster V, Ryden LE, Asinger RW, et
al. ACC/AHA/ESC Guidelines for the management of patients
with atrial fibrillation: executive summary. J Am Coll Cardiol
2001;38:1231– 66.
249. Sherman DG, Dyken ML, Gent M, et al.
Antithrombotic therapy for cerebrovascular disorders: an update.
Chest 1995;108:444S–56S.
250. Mohr JP, Thompson JL, Lazar RM, et
al. A comparison of warfarin and aspirin for the preventionpnrnot1
of recurrent ischemic stroke. N Engl J Med 2001;345:1444 –51.
251. Fuster V, Gersh BJ, Giuliani ER, et
al. The natural history of idiopathic dilated cardiomyopathy.
Am J Cardiol 1981;47:525–31.
252. Pullicino PM, Halperin JL, Thompson
JL. Stroke in patients with heart failure and reduced left
ventricular ejection fraction. Neurology 2000; 54:288 –94.
253. Mas JL, Arquizan C, Lamy C, Zuber
M, et al. Recurrent cerebrovascular events associated with
patent foramen ovale, atrial septal aneurysm, or both. N Engl
J Med 2001;345:1740 – 6.
254. Gullov AL, Koefoed BG, Petersen P,
et al. Fixed minidose warfarin and aspirin alone and in combination
vs adjusted-dose warfarin for stroke prevention in atrial
fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin,
and Anticoagulation Study (AFASAK 2). Arch Intern Med 1998;158:1513–21.
© 2003 by the American Heart Association, Inc., and the
American College of Cardiology Foundation
|
